ArticleProceedings of the National Academy of Sciences of the United States of America2019
The combination of
Oksana B Serebrennikova, Maria D Paraskevopoulou, Elia Aguado-Fraile, Vasiliki Taraslia, Wenying Ren, Geeta Thapa, Jatin Roper, Keyong Du, Carlo M Croce, Philip N Tsichlis
Article in Proceedings of the National Academy of Sciences of the United States of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
5 citing papers in PubMed, 10 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors at 3 institutions in 1 country.
Oksana B SerebrennikovaMolecular Oncology Research Institute, Tufts Medical Center, Boston, MA 02111.
Maria D ParaskevopoulouMolecular Oncology Research Institute, Tufts Medical Center, Boston, MA 02111.
Elia Aguado-FraileMolecular Oncology Research Institute, Tufts Medical Center, Boston, MA 02111.
Vasiliki TarasliaMolecular Oncology Research Institute, Tufts Medical Center, Boston, MA 02111.
Wenying RenMolecular Oncology Research Institute, Tufts Medical Center, Boston, MA 02111.
Geeta ThapaMolecular Oncology Research Institute, Tufts Medical Center, Boston, MA 02111.
Jatin RoperMolecular Oncology Research Institute, Tufts Medical Center, Boston, MA 02111.
Keyong DuMolecular Oncology Research Institute, Tufts Medical Center, Boston, MA 02111.
Carlo M CroceDepartment of Cancer Biology and Genetics, The Ohio State University, Columbus, OH 43210; carlo.croce@osumc.edu philip.tsichlis@osumc.edu.
Philip N TsichlisMolecular Oncology Research Institute, Tufts Medical Center, Boston, MA 02111; carlo.croce@osumc.edu philip.tsichlis@osumc.edu.
Tufts Medical Center · USMolecular Oncology (United States) · USThe Ohio State University · US
Funding
Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI DONNA NIEDZWIECKI · 1985 to 2026
$174.8M
Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
Cancer Gene Discovery to Identify Targetable TargetsR35CA197706 · NCI · OHIO STATE UNIVERSITY · PI CROCE, CARLO M · 2015 to 2021
$6.4M
Biologic and Therapeutic Significance of miR-155 in AMLR01CA201184 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI CROCE, CARLO M, GARZON, RAMIRO · 2016 to 2020
$2.7M
The role of Mtss1 in Hedgehog-mediated intestinal cancer stem cell functionK08CA198002 · NCI · TUFTS MEDICAL CENTER · PI ROPER, JATIN · 2015 to 2019
Most normal and tumor cells are protected from tumor necrosis factor α (TNFα)-induced apoptosis. Here, we identify the MAP3 kinase tumor progression locus-2 (TPL2) as a player contributing to the protection of a subset of tumor cell lines. The combination of
Indexed as
ApoptosisCarcinomaCaspase 8Caspase InhibitorsDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticGene Knockdown TechniquesHeLa CellsHumansMacrophagesMAP Kinase Kinase KinasesMicroRNAsPhosphorylationProto-Oncogene ProteinsReceptor-Interacting Protein Serine-Threonine KinasesRNA, Small InterferingCaspase 8Caspase InhibitorsMAP3K8 protein, humanMAP Kinase Kinase KinasesMicroRNAsMIRN21 microRNA, humanProto-Oncogene ProteinsReceptor-Interacting Protein Serine-Threonine KinasesRIPK1 protein, humanRNA, Small InterferingTumor Necrosis Factor-alphaapoptosiscaspasesynthetic lethalityTNFαTPL2
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.